Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT03994601	TitleEstudio de inmunoterapia en investigación de BMS-986288 solo y en combinación con nivolumab en cánceres sólidos avanzados.	Fase Fase 1	Date Added 2019-06-21	Ubicación California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canadá Chile Francia Italia España	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas BMS-986288, Nivolumab, Opdivo	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03970382	TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors	Fase Fase 1	Date Added 2019-05-31	Ubicación California, United States Illinois, United States New York, United States Tennessee, United States Washington, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Suspendido	Drogas IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT03983993	TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2019-06-12	Ubicación Georgia, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Niraparib, panitumumab, Vectibix, Zejula	Etiquetas MSS/ MMRp
NCT ID NCT03745326	TitleAdministración de linfocitos de sangre periférica transducidos con un receptor murino de células T que reconoce la variante G12D del RAS mutado en pacientes HLA-A*11:01	Fase Phase 1, Phase 2	Date Added 2018-11-19	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03280511	TitleQuimioterapia adyuvante con aerosol intraperitoneal presurizado (PIPAC) en pacientes con cáncer de colon de alto riesgo resecado	Fase Fase 2	Date Added 2017-09-12	Ubicación Dinamarca	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas PIPAC	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05141474	TitleEvaluación de la seguridad y tolerabilidad de la terapia ex vivo con linfocitos infiltrantes de tumor (TIL) seleccionados por neoantígenos de nueva generación en tumores epiteliales avanzados y tumores sólidos resistentes al bloqueo de puntos de control inmunitario (ICB).	Fase Fase inicial 1	Date Added 2021-12-02	Ubicación España	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05215574	TitleEstudio de NGM831 como monoterapia y en combinación con pembrolizumab en tumores sólidos avanzados o metastásicos	Fase Fase 1	Date Added 2022-01-31	Ubicación Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas NGM831, NGM831 plus pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04332653	TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Fase Fase 1	Date Added 2020-04-03	Ubicación Florida, United States Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas NT-I7, Pembrolizumab	Etiquetas MSS/ MMRp
NCT ID NCT03851614	TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors	Fase Fase 2	Date Added 2019-02-22	Ubicación Canadá	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Cediranib, durvalumab, Olaparib	Etiquetas MSS/ MMRp
NCT ID NCT03832855	TitleEvaluación de la inmunogenicidad de pING-hHER3FL	Fase Fase 1	Date Added 2019-02-06	Ubicación North Carolina, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas pING-hHER3FL	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 111 to 120 of 299 entries